As covered by CCTV in the report, as a subsidiary of Tasly, Tasly Biopharma has independently developed Category I Major Innovative Biologic Drug PUK, whose acute ischemic stroke indication Phase III clinical trial and acute pulmonary embolism Phase II clinical trial have completed the enrollment, and it is expected to submit a new drug application this year.
PUK, which is the only approved recombinant human prourokinase product in China, was included in the “Catalog of Medicines” covered by National Medical Insurance System twice in 2017 and 2019. We believe that PUK has huge potential to become a blockbuster thrombolytic drug in China.